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Indoleamine 2,3-dioxygenase (IDO), an enzyme that degrades the essential amino
acid L-tryptophan along the kynurenine pathway, exerts immunomodulatory
effects in a number of diseases. IDO expression is increased in tumor tissue and
in draining lymph nodes; this increase is thought to play a role in tumor evasion
by suppressing the immune response. A competitive inhibitor of IDO is currently
being tested in clinical trials for the treatment of relapsed or refractory solid
tumors, but the efficacy of IDO inhibition in colorectal tumors remains to be fully
elucidated. In this study, we investigated the effect of IDO deficiency on colon
tumorigenesis in mice by genetic deletion and pharmacological inhibition. Ido1-
deficient(/) mice were crossed with ApcMin/+ mice or were administered az-
oxymethane with or without dextran sodium sulfate. Ido1 deficiency did not lead
to significant differences in the size and number of colon tumors. Similarly, the
pharmacological inhibition of IDO using 1-methyltryptophan (1-mT) also resulted
in no significant differences in tumor size and number in ApcMin/+ mice. However,
Ido1 deficiency altered the immune response in the tumor microenvironment,
showing a significant increase in mRNA expression of pro-inflammatory cytokines
and a significant decrease in the number of Foxp3-positive regulatory T cells in
the colon tumors of Ido1(/) mice. Importantly, 1-mT treatment also significantly
altered cytokine expression in the colon tumor tissues. These results suggest that
IDO inhibition alone cannot sufficiently suppress colon cancer development in
mice despite its immunomodulatory activity in the tumor microenvironment.
I ndoleamine 2,3-dioxygenase (IDO) is an intracellular enzymethat degrades essential amino acid L-tryptophan to N-form-
ylkynurenine, which is the first and rate-controlling step in the
kynurenine pathway.(1) IDO has two paralogs, IDO1 and IDO2.
Both enzymes catalyze the degradation of tryptophan but their
distribution differs among organs.(2) IDO exerts immunosup-
pressive effects by reducing the local concentration of trypto-
phan and increasing the production of immunomodulatory
tryptophan metabolites, which have various effects on immune
cells.(3,4) For instance, the metabolites suppress proliferation
and promote apoptosis of T lymphocytes,(2–4) and induce differ-
entiation of naive T cells into regulatory T cells (Tregs).
IDO has attracted considerable attention as a novel target for
the development of cancer therapeutics.(5) Some human tumors
express higher IDO levels than normal tissues; this may con-
tribute to their escape from attack by the host immune sys-
tem.(6) Treatment with an IDO inhibitor reduces the volume of
tumors that were transplanted into mice preimmunized with
the tumor antigen.(6) This suggests that IDO inhibitors may
exert antitumor effects by suppressing immune tolerance. In
keeping with this hypothesis, a competitive inhibitor of IDO,
1-methyltryptophan (1-mT), is currently in clinical trials for
the treatment of some relapsed or refractory solid tumors.(5)
Because IDO expression has been reported in human colorectal
cancer (CRC),(7–9) it is believed that CRC could be potentially
treated by using IDO inhibitors. However, the clinical signifi-
cance of IDO expression in CRC still seems to be a controver-
sial topic. Previous studies have indicated that, unlike in other
tumors such as endometrial carcinoma,(10) ovarian carci-
noma(11) and hepatocellular carcinoma,(12) in CRC, the IDO
expression levels are not correlated with the overall survival of
patients.(7,9) However, one recent study shows that tumoral
IDO1 expression at the invasive front was significantly associ-
ated with overall survival.(8)
The role of IDO expression in the tumor microenvironment
of CRC remains largely unknown. The association of IDO
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expression and the infiltrating T lymphocytes in human CRC
has been evaluated in previous studies, but consistent results
have not been obtained.(7,8) While an initial study showed that
higher IDO expression was significantly associated with a
reduction of CD3+ infiltrating lymphocytes in human CRC,(7)
a more recent study indicated the lack of a significant correla-
tion between IDO1 expression levels and the number of CD3+
or CD8+ T lymphocytes.(8) Because the effect of IDO expres-
sion on other immune regulatory factors such as cytokine
expression is yet to be elucidated, further studies are needed to
examine the role of IDO in the tumor microenvironment.
Chang et al. (2011) and Thaker et al. (2013) examine the
effect of IDO inhibition on colon carcinogenesis in rodent
models.(13,14) In models of colitis-associated colon tumor, Tha-
ker et al. demonstrate the suppression of colon tumor develop-
ment in Ido1 gene-deficient(/) mice and in mice that were
administered a pharmacological inhibitor of IDO1.(14) How-
ever, the study by Chang et al. give contradictory results,
showing an increased development of colitis-associated colon
tumors in Ido1(/) mice.(13) Therefore, further studies are
needed to conclusively demonstrate the role of IDO1 in the
development of colitis-associated colon tumors. In addition,
because IDO inhibition has been reported to severely exacer-
bate colitis,(15–18) the effect of IDO1 inhibition on colon
tumorigenesis should be examined separately from colitis.
In this study, we investigated the effect of genetic deletion of
Ido1 on colon tumorigenesis in an ApcMin/+ mouse model as well
as chemically-induced colon tumor models by using azoxyme-
thane (AOM) with or without dextran sulfate sodium (DSS).
The changes in cytokine expression and subset composition of
infiltrating lymphocyte in the tumor microenvironment were
also examined in colon tumors. In addition, we used pharmaco-
logic approaches with IDO inhibitors in ApcMin/+ mice to exam-
ine the effects of these compounds in colon tumors.
Materials and Methods
Animals. Ido1(/) mice of the C57BL ⁄6J background and
ApcMin/+ mice of the C57BL ⁄6J background were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA). The
mice were maintained under controlled conditions (23  2°C
and 12-h light:dark cycle). All animals were handled in accor-
dance with the regulations for animal experiments at Gifu Uni-
versity.
Colon tumorigenesis. Animal models of AOM-induced colon
tumorigenesis were generated according to previous studies
with slight modification.(19,20) Five-week-old Ido1(/) or Ido1-
wild-type(+/+) mice received weekly i.p. injection of 10 mg ⁄kg
AOM (Sigma-Aldrich, St. Louis, MO, USA) for 5 weeks. The
mice were maintained without further treatment and killed
10 weeks after the last dose of AOM. In addition, a
colitis-associated colon tumorigenesis model was produced as
previously described.(21) In the colitis-associated model, the
5-week-old Ido1(/) or Ido1(+/+) mice received a single AOM
injection (10 mg ⁄kg i.p.) followed by administration of 2%
DSS (molecular weight 36 000–50 000; MP Biomedicals,
Santa Ana, CA, USA) in drinking water for 7 days. Fifteen
weeks after the first AOM injection, all surviving mice were
killed and analyzed.
To investigate the effects of Ido1 deficiency in the ApcMin/+
mouse model, Ido1(/) mice were crossed with ApcMin/+ mice
to generate ApcMin/+;Ido1(/) and ApcMin/+;Ido1(+/+) offspring
for analyses. The mice were maintained without treatment and
were killed at the age of 20 weeks.
1-mT treatment. Thirteen-week-old ApcMin/+ mice were
assigned to three groups: 1-L-mT treatment, 1-D-mT treatment and
vehicle treatment (control) groups. The mice were given 1-L-mT
or 1-D-mT (both purchased from Sigma-Aldrich) in their drinking
water (5 mg ⁄mL in alkaline water [pH 11.0]) or alkaline water
adjusted to pH 11.0 (control group) for 7 weeks. All surviving
mice were killed at 20 weeks of age and analyzed.
In the preliminary examination of the inhibitory effect of
1-mT on IDO activity in vivo, 13–17-week-old ApcMin/+ mice
were administered 1-L-mT or 1-D-mT in drinking water at the
same concentration for 7 days, and the serum concentrations
of L-kynurenine and L-tryptophan were measured using HPLC
as previously reported(22) to calculate the kynurenine-to-trypto-
phan ratio.
Macroscopic analysis and sample preparation. The colon was
opened longitudinally and examined for tumor number and
size. Digital images were used to measure precise tumor
dimensions, and the greatest dimension was adopted as the
tumor size for each specimen. Macroscopically identified
tumors of sufficient size were cut in half in the direction of
the long axis. One half was fixed in 10% buffered formalin for
24 h at room temperature and processed for histological and
immunohistological analyses. The other half of each colon
tumor was analyzed by quantitative PCR. Smaller tumors were
collected for either analysis.
Histological and immunohistochemical analyses. Paraffin-
embedded sections (3-lm-thick) of the colon wall were
prepared and stained with H&E for histological analysis.
Cross-sections of colon wall were routinely cut in ApcMin/+
mice and AOM ⁄DSS-treated mice. Horizontal sections of
colon wall were prepared in AOM alone-treated mice and the
number of intramucosal microadenomas was counted on the
H&E-stained section.(23) Immunohistochemical analyses were
performed as described previously using the following primary
antibodies: rabbit polyclonal anti-IDO (provided by K. Saito,
Kyoto University),(24) rabbit polyclonal anti-Foxp3 (Abcam,
Cambridge, UK), rabbit polyclonal anti-CD3 (DAKO, Glost-
rup, Denmark) and rat monoclonal anti-CD45R ⁄B220 (clone
RA3-6B2; BD Biosciences, San Jose, CA, USA). Double im-
munostaining for IDO and CD11c was performed as described
previously with a slight modification.(16) Ethical approval for
use of archival tissues of human CRC was provided by the
Ethics Committee of Gifu University School of Medicine.
Quantitative real-time RT-PCR. Quantitative real-time RT-PCR
of eight genes of interest (Ifng, Tnf, Il-10, Tgfb, Foxp3, Cd3e,
Ido1 and Ido2) was performed as previously described.(25) The
PCR primers are listed in Table S1. The expression of each
gene was normalized to b-actin (Actb) expression by using the
standard curve method.
Statistical analysis. All data are presented as the mean  SD.
For comparisons between the two groups, the data were ana-
lyzed using the unpaired Student’s t-test with Welch’s correc-
tion or paired t-test. For comparisons between more than two
groups, we used the Kruskal–Wallis test followed by Steel’s
test for comparison with controls. P < 0.05 was considered
statistically significant.
Results
IDO expression is significantly increased in colon tumor tis-
sue. We first tested whether IDO is expressed in mouse colon
tumors as well as in human CRC(7–9) by means of immunohis-
tochemistry. We examined colon tumors and intramucosal mic-
roadenomas (i.e. colonic pre-neoplastic lesions) that developed
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in three different ApcMin ⁄ + mice (n = 7 and 122, respectively).
The cytoplasmic IDO expression was significantly increased in
the colon tumor tissues compared with that in the adjacent
non-tumor tissues, whereas the expression remained at normal
or slightly elevated levels in most of the microadenomas (24.6
and 63.1%, respectively) (Fig. 1a). In addition, IDO was
highly expressed in the inflammatory cells infiltrating the
tumor stromas, including CD11c-positive dendritic cells
(Figs 1a and S1). A similar expression pattern of IDO was
observed in human CRC (n = 5, Fig. 1b), as previously
reported.(7–9)
Ido1 deficiency does not significantly affect colon tumor devel-
opment. To investigate the role of IDO1 in colon tumorigene-
sis, the effects of Ido1 deficiency were examined in various
mouse models. First, based on the immunostaining data
(Fig. 1a), we quantified the colon tumors that developed in
ApcMin/+;Ido1(/) and ApcMin/+;Ido1(+/+)mice. Macroscopic
analysis revealed that there was no significant difference in the
number and size of the tumors between these genotypes
(Fig. 2a). In addition to the ApcMin/+ mouse model, chemically
induced colon tumorigenesis models were used. In the mice
administered AOM alone, a small number of tumors were
identified macroscopically (Fig. 2a); therefore, the number and
size of intramucosal microadenomas were analyzed on the hor-
izontal section of colon mucosa and no significant differences
were observed between Ido1(/) and Ido1(+/+) mice (Fig. 2c).
Because the administration of AOM alone failed to induce a
sufficient number of tumors, we used the colitis-associated
tumorigenesis model in which mice were given the potent
tumor promoter DSS following AOM administration. In the
colitis-associated tumorigenesis model, the number of macro-
scopically identified colon tumors increased as expected and
showed a tendency to be smaller in Ido1(/) mice than in
(a)
(b)
Fig. 1. Immunohistochemical staining for indoleamine 2,3-dioxygen-
ase (IDO) in the colon lesions of ApcMin/+ mice and human colorectal
cancer (CRC). (a) Intramucosal microadenoma (upper) and adenocarci-
noma (lower) developed in the colons of ApcMin/+ mice. The inset in
the lower panel shows a double positive cell for IDO (brown) and the
dendritic cell marker CD11c (blue) in the tumor stroma (see also Fig.
S1). (b) Human CRC. Arrowheads indicate microadenoma and the
dashed line delineates the border between tumor tissues and non-




Fig. 2. Effects of Ido1 deficiency on colon tumorigenesis in mice. (a)
Average number and size of colon tumors in ApcMin/+, azoxymethane
(AOM)-treated, and AOM ⁄ dextran sulfate sodium (DSS)-treated mice.
ApcMin/+ mice were examined at the age of 20 weeks and AOM-trea-
ted and AOM ⁄ DSS-treated mice were examined 20 weeks after the
first AOM injection. (b) Representative images of colon adenocarcino-
mas in ApcMin/+ mice with the Ido1(/) and Ido1(+/+) genotypes. Scale
bars: 200 lm (left panels) and 100 lm (right panels). (c) Representa-
tive images and the number and size (the number of aberrant crypts
in each lesion) of intramucosal microadenomas in AOM-treated mice.
Scale bars: 50 lm (left panels). Data are presented as the means  SD.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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Ido1(+/+) mice, but this difference was not statistically signifi-
cant owing to individual variability (Fig. 2a). All the colon
tumors had similar sizes in the colitis-associated model
(Fig. 2a). Subsequently, the tumors were microscopically ana-
lyzed in detail, but the Ido1 deficiency did not affect the inci-
dences of adenomas and adenocarcinomas or the histological
grade of the tumors, including the degrees of invasiveness and
differentiation, in any model (Table 1, Figs 2b and S2). These
results indicated that Ido1 deficiency does not significantly
affect colon tumor development in mice.
Ido1 deficiency alters cytokine expression in colon tumor
microenvironment. IDO is mainly expressed in the dendritic
cells in tumor stroma and tumor draining lymph nodes where
it suppresses immune reactions. In the present study, IDO-
expressing dendritic cells were also observed in tumor stroma
in mouse colon tumors (Fig. 1a, inset in the lower right panel
and Fig. S1). Therefore, to investigate the effect of IDO1 defi-
ciency on the production of pro-inflammatory and anti-inflam-
matory cytokines, we examined the mRNA expression levels
of Ifng, Tnf, Il-10 and Tgfb in the mouse colon tumor tissue.
In both ApcMin/+ and AOM ⁄DSS-treated mice, the expression
of Ifng in the colon tumor tissue was significantly higher in
Ido1(/) mice than in Ido1(+/+) mice (Fig. 3a,b). Ido1 defi-
ciency also led to a significantly higher expression of Tnf in
the colon tumors of ApcMin/+ mice (Fig. 3a), while no signifi-
cant difference was observed between mice with the Ido1(/)
and Ido1(+/+) genotypes in AOM ⁄DSS-treated mice (Fig. 3b).
In contrast, there were no significant differences in the expres-
sion of Il-10 and Tgfb between mice with the two genotypes in
both ApcMin/+ and AOM ⁄DSS-treated mice (Fig. 3a,b). These
results indicate that IDO1 alters the expression of pro-inflam-
matory cytokines in colon tumor tissue. In addition, Ido2
expression was detected in mouse colon tumor tissues, similar
to that reported in human CRC;(26) however, no significant dif-
ference was observed between mice with the Ido1(/) and
Ido1(+/+) genotypes (Fig. 3a,b).
Ido1 deficiency decreases regulatory T cells in colon tumor
microenvironment. IDO promotes the differentiation of naive T
cells into Tregs and the migration of Tregs, which is thought
to be one of the key mechanisms of immunosuppression.(27)
Interestingly, a recent study showed the accumulation of regu-
latory T cells in intestinal tumors of ApcMin/+ mice.(28) To clar-
ify the effect of IDO deficiency on Treg infiltration in mouse
colon tumors, we counted the number of lymphocytes that
were positive for Foxp3 (a marker of Tregs) in tumor stroma
by immunohistochemical analysis; and we then calculated the
cellular density per unit area. In addition, expression of Foxp3
and Cd3e mRNA in the homogenized tumor tissue was
assessed by real-time PCR to calculate the Foxp3 ⁄Cd3e ratio,
which serves as a molecular indicator of the proportion of
Tregs to total T-cell content. Immunohistochemically, Foxp3-
positive lymphocytes were scattered in tumor stroma (Fig. 4a).
The density of Foxp3-positive lymphocytes in tumor stroma
was significantly lower in Ido1(/) mice than in Ido1(+/+)




Incidence (%) Histological grade of adenocarcinoma (%)
Adenoma Adenocarcinoma






Ido1 ( ⁄) 21 7 (33.3) 14 (66.7) 5 (35.7) 9 (64.3) 0 (0.0) 6 (42.9) 8 (57.1)
Ido1 (+ ⁄ +) 11 2 (18.2) 9 (81.8) 5 (55.6) 4 (44.4) 0 (0.0) 2 (22.2) 7 (87.8)
AOM-treated mouse
Ido1 ( ⁄) 2 0 (0.0) 2 (100) 0 (0.0) 2 (100) 0 (0.0) 1 (50.0) 1 (50.0)
Ido1 (+ ⁄ +) 3 1 (33.3) 2 (66.7) 0 (0.0) 2 (100) 0 (0.0) 1 (50.0) 1 (50.0)
AOM ⁄ DSS-treated mouse
Ido1 ( ⁄) 13 2 (15.4) 11 (84.6) 7 (63.6) 4 (36.4) 0 (0.0) 6 (46.2) 5 (38.5)
Ido1 (+ ⁄ +) 14 2 (14.3) 12 (85.7) 4 (33.3) 8 (66.7) 0 (0.0) 6 (42.9) 6 (42.9)
1-mT-treated ApcMin/+ mouse
1-L-mT treatment 31 5 (16.1) 26 (83.9) 11 (42.3) 15 (57.7) 0 (0.0) 12 (46.2) 14 (53.8)
1-D-mT treatment 32 2 (6.3) 30 (93.8) 11 (36.7) 19 (63.3) 0 (0.0) 18 (60.0) 12 (40.0)
Control 35 5 (14.3) 30 (85.7) 11 (36.7) 19 (63.3) 0 (0.0) 16 (53.3) 14 (4.7)
(a)
(b)
Fig. 3. Relative mRNA expression of pro-inflammatory and anti-
inflammatory cytokines and Ido2, in colon tumor tissues in ApcMin/+
(a) and AOM ⁄ DSS-treated mice (b). Data are presented as the
means  SD. *P < 0.05 by Student’s t-test.
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mice, as determined after AOM ⁄DSS treatment, whereas there
were no significant differences between genotypes in the den-
sity of CD3-positive cells (Fig. 4c). The ratio of Foxp3 ⁄CD3-
positive cells was slightly lower in Ido1(/) mice than in
Ido1(+/+) mice after treatment with AOM ⁄DSS and the Foxp3
⁄Cd3e mRNA expression ratio was lower, but the differences
were not statistically significant (Fig. 4c). Similarly, in ApcMin/
+ mice, although no significant differences were observed, the
Treg density was lower in Ido1(/) mice than in Ido1(+/+)
mice (Fig. 4b). Although there were fewer CD45R-positive
cells than CD3-positive cells in the tumors, the density of
CD45R-positive cells was significantly lower in Ido1(/) mice
than in Ido1(+/+) mice after AOM ⁄DSS treatment (Fig. 4c).
These results indicate that IDO1 deficiency can suppress the
differentiation into Tregs and ⁄or migration of Tregs, and, thus,
reduce the Treg population in colon tumor tissue.
IDO inhibitors do not reduce colon tumor burden, but alter
cytokine expression in tumor microenvironments. The competi-
tive IDO inhibitor 1-mT has two isomers, 1-L-mT and 1-D-
mT.(29) In the preliminary assessment of the inhibitors, the
serum kynurenine-to-tryptophan ratio decreased significantly
only after 1-L-mT administration in ApcMin/+ mice (Fig. 5a).
However, considering that the 1-mT form actually used in clin-
ical trials is 1-D-mT, and recent studies have suggested that its
effect is unlikely to be dependent on inhibition of the enzy-
matic activity of IDO,(30,31) the longer-term effects of both iso-
mers were investigated in the colon tumors of ApcMin/+ mice.
Macroscopically, the average number and size of colon tumors
were similar in 1-L-mT-treated, 1-D-mT-treated and control
groups (Fig. 5b). In addition, the microscopic examination
revealed that there were no significant differences in histologi-
cal grades of the colon tumors and the degree of inflammation
among 1-L-mT, 1-D-mT and control groups (Table 1). In con-
trast, although it was not possible to simply define the effects
of the IDO inhibitors as immunopotentiating, the cytokine
expression in the colon tumor tissues changed significantly fol-
lowing 1-L-mT or 1-D-mT treatment (Fig. 5c). The 1-L-mT
treatment significantly decreased the expression of Il-10 and
Tgfb, consistent with the immunosuppressive role of IDO, but
also significantly decreased Tnf expression (Fig. 5c). Similarly,
the 1-D-mT treatment significantly changed the expression of
Il-10 and Tnf (Fig. 5c). The expression of Ido1 and Ido2 was
also examined to investigate whether IDO expression was
changed in response to IDO inhibitors, but it decreased in the
colon tumors of 1-L-mT-treated and 1-D-mT-treated mice.
These results indicate that IDO inhibitors do not affect colon
tumor development but can alter cytokine expression in colon
tumor tissues in mice.
Discussion
Increased IDO expression has been reported in human CRC,(7–9)
but its biological significance is yet to be fully elucidated.
Because previous rodent studies were conducted in a chemi-
cally-induced colitis-associated model,(13,14) we used an
ApcMin/+ mouse model to evaluate the role of IDO in colon
tumorigenesis separately from colitis. In the present study, by
immunohistochemistry, we show that IDO is expressed in mouse
colon tumors as well as in human CRC, suggesting that IDO has
some roles in mouse colon tumorigenesis. However, our results
show that Ido1 deficiency did not lead to any changes in the
number, size and histological grade of the colon tumors devel-
oped in ApcMin/+ mice. Consistent with this result, the pharma-
cological inhibition of IDO also did not have any effect on
colon tumor development in ApcMin/+ mice. These results sug-
gest that IDO inhibition alone is not sufficient to affect colon
cancer development. Although we did not use the colitis-associ-
ated tumorigenesis model, intratumoral inflammation would still
be involved in the development of colon tumors. IDO inhibition
would have a promoting effect on colon tumorigenesis through
intratumoral inflammation enhancement, but would also exert a
suppressing effect by enhancing the anti-tumor immune
response. Therefore, the lack of an effect of IDO inhibition on
colon tumor development might reflect a balance of the promo-
tion and suppression effects. In contrast, in human CRC, higher
IDO expression was significantly correlated with the frequency




Fig. 4. Effects of Ido1 deficiency on tumor-infiltrating lymphocytes
in colon tumor tissues. (a) Immunohistochemical staining for Foxp3
(upper panels) and CD3 (lower panels) in colon tumors of ApcMin/+
mice. Scale bars: 100 lm (left panels) and 20 lm (right panels). (b,c)
The densities of Foxp3-positive cells (Tregs), CD3-positive cells (T cells)
and CD45R-positive cells (B-cells), the ratio of Foxp3-positive cells to
CD3-positive cells assessed by immunohistochemistry (IHC), and the
ratio of Foxp3 ⁄ Cd3e mRNA expression assessed by quantitative PCR in
tumor tissues of ApcMin/+ mice (b) and AOM ⁄ DSS-treated mice (c).
Data are presented as the means  SD. *P < 0.05 by Student’s t-test.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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was significantly associated with overall survival, suggesting a
role for IDO in tumor invasion.(8) The findings from human CRC
suggest the possibility that IDO may be involved in tumor pro-
gression at more advanced stages; however, it is difficult to evalu-
ate this in mouse models owing to the lack of available models
that reproduce highly invasive and metastatic colon tumors. Fur-
thermore, although the enzymatic activity of IDO2 has been
reported to be far less than that of IDO1(30,31) and the compensa-
tory increases in Ido2 mRNA expression were not observed in
colon tumors of Ido1(/) mice, we cannot completely exclude
the possibility that IDO2 may play a complementary role in
IDO1-deficient conditions. In addition, a recent study revealed
the novel function of IDO2 as a negative regulator of IDO1.(32)
While IDO1 expression suppressed cell growth with downregula-
tion of cell survival-related proteins, IDO2 co-expression allevi-
ated IDO1-dependent cell growth suppression.(32) Considering
the expression of both Ido1 and Ido2 in human CRC,(26) inhibition
of IDO2 rather than IDO1 can lead to tumor growth suppression.
Further investigations are needed to elucidate the contribution of
IDO2 expression to colon carcinogenesis.
Genetic deficiency of Ido1 has been reported to significantly
affect the development of colitis-associated colon tumors in
mice. However, two previous studies gave opposite results by
showing a significant increase and decrease in colon tumors in
Ido1(/) mice, respectively.(13,14) In the present study, no sta-
tistically significant difference was observed in AOM ⁄DSS-
treated mice, but the colon tumor number was smaller in the
Ido1(/) mice than in the Ido1(+/+) mice. This supports the
hypothesis that IDO1 inhibition suppresses the development of
colitis-associated tumors. However, considering the relation-
ship between inflammation and CRC,(33) the application of
IDO-targeting therapy to patients with colitis-associated tumors
seems to be impractical. It has been reported that IDO inhibi-
tion does not increase the severity of DSS-induced colitis if
DSS is administered at low doses,(34,35) as in the colitis-associ-
ated tumor model used in previous studies(14) and in the pres-
ent study. In contrast, it has been repeatedly demonstrated that
IDO expression is elevated in animal models of colitis, and
that IDO inhibition leads to significantly more severe coli-
tis.(15,16,35) Similarly, IDO1 is highly upregulated in human
colon in inflammatory conditions, such as inflammatory bowel
disease; this upregulated IDO1 expression is thought to be
responsible for suppressing excessive inflammatory reac-
tions.(17,18) These results imply that IDO inhibition could pose
a risk of promoting tumors via worsening of inflammation in
patients with colitis-associated tumors.
The role of IDO in the colon tumor microenvironment
remains largely unknown. The most important finding of the
present study is that IDO inhibition led to significant changes
in the inflammatory response within the tumors, although it
did not affect the colon tumor development in mice. In the
Ido1(/) mice, the expression of pro-inflammatory cytokines




Fig. 5. Effects of indoleamine 2,3-dioxygenase (IDO) inhibitors in
colon tumors of ApcMin/+ mice. (a) Serum kynurenine-to-tryptophan
ratio of ApcMin/+ mice treated with 1-L-mT or 1-D-mT for 7 days. Data
are presented as the means  SD. *P < 0.05 by paired t-test. (b) Aver-
age number and size of colon tumors in ApcMin/+ mice treated with 1-
L-mT or 1-D-mT. ApcMin/+ mice were examined at the age of 20 weeks.
(c) Relative mRNA expression of cytokines and IDO in colon tumor tis-
sues of 1-L-mT-treated and 1-D-mT-treated mice. Data are presented as
the means  SD. *P < 0.05 by Student’s t-test.
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AOM ⁄DSS-treated mice. Because the kynurenine pathway sup-
presses the differentiation of T helper type 1 (Th1) cells,(3)
IDO1 deficiency may cause increased expression of the Th1-
type cytokine IFN-c in local tissues. It should be mentioned
that, while not only genetic deletion but also pharmacological
inhibition of IDO altered the expression of cytokines, there
was no consistent expression change pattern. IDO inhibitors
significantly reduced the expression of anti-inflammatory cyto-
kines. In particular, Il-10 expression was markedly decreased
following both 1-L-mT and 1-D-mT treatments. However,
because the decreased Tnf expression was observed in both 1-
L-mT-treated and 1-D-mT-treated mice, it is not possible to
describe the effect of IDO inhibitors in colon tumors as immu-
nopotentiating. 1-L-mT and 1-D-mT were previously thought to
selectively inhibit IDO1 and IDO2, respectively.(29) However,
recent studies have shown that 1-L-mT inhibits not only IDO1
but also IDO2, although it is more effective for IDO1 than for
IDO2.(30,31) Interestingly, it has been shown that Ido2(/)
mice displayed significantly lower cytokine induction, includ-
ing the induction of IFN-c, and TNF-a, in a contact hypersen-
sitivity model whereas these cytokine levels were elevated in
Ido1(/) mice.(36) Therefore, the decrease in the expression of
Ifng and Tnf in 1-L-mT-treated mice might be due to IDO2
inhibition, while the significant elevation in the expression of
Ifng and Tnf in Ido1-deficient mice was caused by IDO1 defi-
ciency. The cytokine expression change pattern was similar in
1-L-mT-treated and 1-D-mT-treated mice, but the underlying
mechanism is likely to be different. In a previous study using
recombinant mouse IDO, 1-D-mT has been shown to be a poor
inhibitor of both mouse IDO1 and IDO2 without a detectable
inhibition of IDO2 activity, thereby suggesting that its immu-
nomodulatory effect can be independent of the inhibition of
IDO enzymes in mice.(30) Consistent with this finding, the
serum kynurenine-to-tryptophan ratio was not changed after
1-L-mT administration in ApcMin/+ mice.
IDO promotes the differentiation into Tregs and migration
of Tregs, and, thus, plays an important role in suppressing T-
cell-mediated inflammation.(27,37) Previous studies revealed
that IDO expression correlated with increased Tregs infiltration
in several human tumors, including glioma(38) and breast can-
cer.(39) In line with these findings, we found that Ido1 defi-
ciency resulted in a significant decrease in the number and
proportion of Tregs in colon tumor stroma in the AOM ⁄DSS-
treated mice. The accumulation of Tregs in local tissues can
also contribute to the immune evasion of tumors.(40–42) It has
also been reported that elimination of Tregs resulted in a
decrease in the number of skin papillomas, with an improved
antitumor immune response in mice.(43) Therefore, it is possi-
ble that the decreased number of Tregs in colon tumors con-
tributed to a reduced tumor burden in AOM ⁄DSS-treated mice.
A recent study showed that various lymphocyte subsets infil-
trate mouse colon tumors using flow cytometry;(44) therefore,
further studies are needed to comprehensively examine the
changes in lymphocyte subsets following IDO inhibition.
In mouse colon tumors, IDO expression was observed not
only in tumor cells but also in tumor infiltrating cells, includ-
ing dendritic cells. Considering the previous findings in human
tumors, both cell types are likely to contribute to IDO-depen-
dent immune regulation in the tumor microenvironment. In
human CRC, higher levels of IDO expression in tumor cells
were associated with a significant reduction in tumor-infiltrat-
ing T cells.(7) Alternatively, although IDO was identified only
in tumor-infiltrating cells and not in tumor cells in human
hepatocellular carcinomas, IDO mRNA levels correlated sig-
nificantly with the cytokine gene expression,(45) thereby sug-
gesting that IDO-expressing tumor-infiltrating cells play an
independent role in cytokine regulation.
In summary, we have demonstrated that genetic deletion or
pharmacological inhibition of IDO1 alters immune responses,
such as cytokine expression, and the number of Tregs in the
colon tumor microenvironment, but does not significantly
affect mouse colon tumor development. These results suggest
that IDO inhibition alone would not be sufficient to suppress
colon cancer development in mice despite its immunomodula-
tory activity in the tumor microenvironment.
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